2017
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. European Journal Of Heart Failure 2017, 19: 893-900. PMID: 28194841, PMCID: PMC5511088, DOI: 10.1002/ejhf.754.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersDouble-Blind MethodEchocardiographyExercise ToleranceFemaleFollow-Up StudiesHeart Failure, SystolicHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsProcollagenQuality of LifeRetrospective StudiesStroke VolumeTime FactorsVentricular Function, LeftConceptsLV global longitudinal strainGlobal longitudinal strainImpaired LV global longitudinal strainVentricular global longitudinal strainEjection fractionQuality of lifeRELAX trialExercise capacityHeart failureN-terminal pro-brain natriuretic peptideLeft ventricular global longitudinal strainWorse LV global longitudinal strainLog-transformed NT-proBNPPro-brain natriuretic peptideNormal LV ejection fractionLongitudinal strainHeart failure scoreLV ejection fractionPeak oxygen consumptionHFpEF patientsMinnesota LivingDiastolic dysfunctionNT-proBNPSystolic dysfunctionClinical characteristics
2015
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal Of Medicine 2015, 373: 2314-2324. PMID: 26549714, PMCID: PMC4712067, DOI: 10.1056/nejmoa1510774.Peer-Reviewed Original ResearchConceptsHeart failureEjection fractionIsosorbide mononitratePlacebo groupDose regimensWalk distanceLife scoresN-terminal pro-brain natriuretic peptidePro-brain natriuretic peptideEnd pointSignificant between-group differencesIsosorbide mononitrate groupLow daily activityNT-proBNP levelsPrimary end pointSecondary end pointsSubmaximal exercise capacityDose-escalation regimenHours of activityActivity levelsBetween-group differencesDaily activity levelsDaily activitiesActivity toleranceExercise capacity